Confirmed Speakers

**QBW251: a Potent Potentiator of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channel for Treatment of Respiratory Diseases**

Dr Atwood CHEUNG  
(NOVA | TIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States)

**The Discovery of BMS-986177/JNJ-70033093; a FXIa Inhibitor for the Prevention and Treatment of Thrombosis**

Dr Andrew DILGER  
(BRISTOL-MYERS SQUIBB, Princeton, United States)

**First Time Disclosure of BI 425809, a GlyT1 Inhibitor for the Treatment of CNS Diseases**

Dr Riccardo GIOVANNINI  
(BOEHRINGER INGELHEIM, Biberach, Germany)

**Cannabinoid Receptor 2 Agonists on Their Way to Clinics – How Industrial Drug Discovery and Academic Research Can Cross-Fertilize Each Other**

Dr Uwe GREther  
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

**The Discovery of LTT462, a Potent ERK Inhibitor for the Treatment of Advanced Solid Tumors Harboring MAPK Pathway Alterations**

Dr Woosok HAN  
(NOVA | TIS INSTITUTES FOR BIOMEDICAL RESEARCH, Songpa-gu, Korea, South)

**Discovery of SCO-267, a First-in-class GPR40 Full Agonist, as a Promising Candidate for the Treatment of Type 2 Diabetes Mellitus, Obesity, and NASH**

Dr Naoyoshi NOGUCHI  
(SCOHIA PHARMA, INC., Fujisawa, Japan)

**Discovery of AZD8154, a Dual PI3K?? Inhibitor, as an Inhaled Treatment for Asthma**

Dr Matthew W. D. PERRY  
(ASTRAZENECA, Gothenburg, Sweden)

**Discovery of the AhR Antagonist BAY 2416964; a New Clinical Candidate for Cancer Immunotherapy**

Dr Norbert SCHMEES  
(BAYER PHARMACEUTICALS, Berlin, Germany)
GB1211, the First Orally Available Galectin/Galectin 3 Inhibitor to Be Taken into Clinic as a Potential Treatment for Non Alcoholic Steatohepatitis (NASH)

Dr Fredrik ZETTERBERG
(GALECTO BIOTECH, Gothenburg, Sweden)